Medical oncologist and cancer researcher specializing in Prostate Cancer. Chief Clinical Officer, City of Hope Arizona, Professor of Molecular Medicine,Tgen
Phoenix, AZ
Joined July 2019
- Tweets789
- Following623
- Followers1.3K
- Likes497
Alan H Bryce retweeted
@BGarmezy with 1st report of an AR RIPTAC - JNJ-6143 in metastatic castration resistant #prostatecancer showing good PSA responses across aggressive molecular subtypes, median duration 11 months. New mechanism to degrade androgen receptor is active!
@oncoalert #ESMO26 @myESMO
Alan H Bryce retweeted
JNJ-6143, first-in-class oral AR-BRD4 RIPTAC, phase 1 mCRPC: a wide window between efficacy and safety. n=105, doses 12.5 to 150 mg.
📈 50 mg daily: PSA50 77%, PSA90 48%, confirmed ORR 69%, after a median 4 prior lines
📊 PSA declines seen from 12.5 to 150 mg. 66% of all patients still on drug
🔍 At 50 mg: 58% any-grade TRAEs, no serious TRAEs. Median DOR 11.0 months, CI 5.9 to NE
Activity across a 12-fold dose range. Phase 2 is open at 50 mg.
Congrats to @BGarmezy on the presentation and all the investigators.
#ESMO26 #ProstateCancer #mCRPC #GUonc
Alan H Bryce retweeted
🌟 Congratulations @WalterStadler5 who will receive the KCA's Nicholas J. Vogelzang Humanitarian Award at our upcoming #IKCSNA26 in November! We are proud to recognize his record of outstanding service and compassion in #kidneycancer care. Read more: kidneycancer.org/2026-ikcsna…
Alan H Bryce retweeted
Congrats to Dr. Mary-Ellen Taplin @DanaFarber_GU 👉 “@PCF_News Women in Science Lifetime Achievement Award at #PCFRetreat26! 🎉 a career spent following the questions & putting patients first. A well-deserved standing ovation. 👏 @PCF_Science @urotoday @DrChoueiri @DanaFarber
Alan H Bryce retweeted
In the @PCF_Science #PCFretreat26 , enjoyed the brilliant talk by, @mishabeltran @DanaFarber_GU 👉Mechanism of resistance to PSMA directed RLT Rx, tips for young investigators, and the value of team science (quote from Dr. Felix Feng) @PCF_Science @urotoday @DanaFarber
The VA leading the way. Congratulations to all of the physicians for overcoming barriers and implementing best practices.
In the Veterans Affairs health system, active surveillance or watchful waiting for favorable-risk #ProstateCancer increased from 27% to 93% for low-risk disease and from 14% to 61% for favorable intermediate-risk disease. ja.ma/4cnGmcs
Alan H Bryce retweeted
We’re hiring!
We need a Biostatistician to join our Urology team at @MayoUrology in Arizona.
This individual will work closely with our faculty on clinical trials, statistical analyses, manuscripts, and general research across urology.
Link below: fa-euwp-saasfaprod1.fa.ocs.o…
Dr Kyle was a giant of Medicine in a way that few of us can ever aspire to. His transformational impact on hematology was in no way fortuitous or accidental, but the direct result of his tireless work ethic and understated brilliance. He was also the consummate gentleman and an extraordinary mentor. I consider it one of the great blessings of my career that my first papers as an intern were with Dr Kyle. I still have the first drafts almost entirely covered by his red pen corrections, each one of which was precise, illuminating, and irrefutable. God Bless you Dr Kyle. Thank you for your generosity and kindness.
We are deeply saddened by the passing of Robert A. Kyle, MD, founder and first president of the International Myeloma Society. Dr. Kyle’s research changed how the medical community understands multiple myeloma and the conditions that can precede it. He was also a teacher and mentor whose influence can be seen in generations of clinicians and scientists working in the field today.
From helping convene the first International Myeloma Workshop in 1987 to founding IMS and serving as its first president, Dr. Kyle believed that progress depended on experts working together across borders, with patients always at the center. That commitment to science, collaboration and patient care remains at the heart of IMS. We extend our deepest condolences to Dr. Kyle’s family, friends, colleagues and the many patients whose lives he touched. myelomasociety.org/rememberi…
A special moment at our USPCC conference when the FDA approval for Pluvicto in APMS occurred mid conference. Congratulation to the study leaders- our friends and mentors @sartor_oliver @DrScottTagawa and Michael Morris, and congratulations to @novartis and to the patients and staff who made this study a success.
Alan H Bryce retweeted
🚨Spectacular oral presentation at #ASCO26 from @RWinayak from @cityofhope on 1L CBM588 + ICI-based tx in mRCC showing improved outcomes in those w/ stool dysbiosis. Phase III BIOFRONT trial to further assess! @COHMedOnc @COHUroOnc @ASCOTECAG – at Chicago, IL
Indeed. That’s why the surgery without adt sub study is so important for the readout against the current surgical soc.
Also, the study patients largely received salvage radiation on progression so the secondary endpoints reflect that.
From the article supplementary data @nejm
Ha! We love this video. And having been of a certain age when the original dropped, I’ve sung it as Bryce Bryce baby more times than I care to admits.
Congratulations to Arsenal and my many friends who support them!
Especially @AlanBryce9 and his son Declan!
@DrChoueiri @cdanicas @DrCols
Bryce, Bryce baby!
youtube.com/watch?v=1xHLdfCI…
Key takeaways for rucaparib in BRCA mutated mCRPC:
- Drug discontinuation rate in the rucaparib arm of 14% vs 22% in the ARPI or Doce control arm
- median onset of cytopenias is over 2 months, meaning plenty of time to see it coming and manage preventatively
- Median Rucaparib dose intensity over 98%, meaning full dose was given for over 98% of total doses administered
Safety of rucaparib vs docetaxel or second-generation androgen receptor pathway inhibitor therapy for patients with #mCRPC and a BRCA mutation in #TRITON3. Presentation by @AlanBryce9 @cityofhope. #AUA26 written coverage by @RKSayyid @UAUrology > bit.ly/3ROWcFh
Alan H Bryce retweeted
Safety of rucaparib vs docetaxel or second-generation androgen receptor pathway inhibitor therapy for patients with #mCRPC and a BRCA mutation in #TRITON3. Presentation by @AlanBryce9 @cityofhope. #AUA26 written coverage by @RKSayyid @UAUrology > bit.ly/3ROWcFh
25% discordance between PSA and radiographic progression is also what we saw in PREVAIL and CHAARTED so the finding is clearly consistent. If it feels high that is likely because your real world definition for PSA progression is more liberal.
nature.com/articles/pcan2016…
sciencedirect.com/science/ar…
I did struggle with this despite being kindly involved in some of the studies.
25% feels high but anecdote versus data never a good thing. @Prof_IanD @ChrisSweens1 guide me.
No PSA progression but LDH, LFTs, FBC, Albumin. Would they miss this?
It’s clearly more than I feel clinically which would be closer to 10%
@Silke_Gillessen @alison_tree @AdamSharpMedOnc @AlanBryce9